{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:14:35Z","timestamp":1791328475399,"version":"4.3.1"},"reference-count":310,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OncoImmunology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.4161\/onci.20931","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T18:33:30Z","timestamp":1339698810000},"page":"894-907","source":"Crossref","is-referenced-by-count":214,"title":["Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy"],"prefix":"10.1080","volume":"1","author":[{"given":"Erika","family":"Vacchelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf Herv\u00e9","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Galon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Saut\u00e8s-Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(85)90275-2","article-title":"Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product","volume":"42","author":"Anderson","year":"1985","journal-title":"Cell"},{"key":"R2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0092-8674(85)90274-0","article-title":"Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product","volume":"42","author":"Anderson","year":"1985","journal-title":"Cell"},{"key":"R3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/276565a0","article-title":"A gene complex controlling segmentation in Drosophila","volume":"276","author":"Lewis","year":"1978","journal-title":"Nature"},{"key":"R4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.221.4605.23","article-title":"Molecular genetics of the bithorax complex in Drosophila melanogaster","volume":"221","author":"Bender","year":"1983","journal-title":"Science"},{"key":"R5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"R6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0092-8674(00)80172-5","article-title":"The dorsoventral regulatory gene cassette sp\u00e4tzle\/Toll\/cactus controls the potent antifungal response in Drosophila adults","volume":"86","author":"Lemaitre","year":"1996","journal-title":"Cell"},{"key":"R7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"R8","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1126\/science.270.5243.1804","article-title":"A receptor kinase-like protein encoded by the rice disease resistance gene, Xa21","volume":"270","author":"Song","year":"1995","journal-title":"Science"},{"key":"R9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1097-2765(00)80265-8","article-title":"FLS2: an LRR receptor-like kinase involved in the perception of the bacterial elicitor flagellin in Arabidopsis","volume":"5","author":"G\u00f3mez-G\u00f3mez","year":"2000","journal-title":"Mol Cell"},{"key":"R10","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1073\/pnas.0502272102","article-title":"The evolution of vertebrate Toll-like receptors","volume":"102","author":"Roach","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1189\/jlb.0103026","article-title":"TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG","volume":"74","author":"Heldwein","year":"2003","journal-title":"J Leukoc Biol"},{"key":"R14","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/IAI.71.8.4238-4249.2003","article-title":"Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Gu\u00e9rin peptidoglycan","volume":"71","author":"Uehori","year":"2003","journal-title":"Infect Immun"},{"key":"R15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"R16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"R17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrd1880","article-title":"From the analyst\u2019s couch: TLR-targeted therapeutics","volume":"4","author":"Hoffman","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"R18","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"R19","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMp078053","article-title":"Introducing HPV vaccine in developing countries--key challenges and issues","volume":"356","author":"Agosti","year":"2007","journal-title":"N Engl J Med"},{"key":"R20","doi-asserted-by":"crossref","DOI":"10.4161\/onci.20696","article-title":"Trial Watch - Experimental Toll-like receptor agonists for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunol"},{"key":"R21","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/j.ijid.2009.12.003","article-title":"Robert Koch and the \u2018golden age\u2019 of bacteriology","volume":"14","author":"Blevins","year":"2010","journal-title":"Int J Infect Dis"},{"key":"R22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2011.00021","article-title":"Edward jenner and the small pox vaccine","volume":"2","author":"Smith","year":"2011","journal-title":"Front Immunol"},{"key":"R23","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/514155","article-title":"Infection of swine with Mycobacterium bovis as a model of human tuberculosis","volume":"176","author":"Bolin","year":"1997","journal-title":"J Infect Dis"},{"key":"R24","first-page":"903","article-title":"Mycobacterium bovis tuberculosis: from animal to man and back","volume":"8","author":"Fritsche","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM195109272451305","article-title":"BCG vaccination","volume":"245","author":"Partenheimer","year":"1951","journal-title":"N Engl J Med"},{"key":"R26","unstructured":"Tuberculosis in the UK. Annual report on tuberculosis surveillance in the UK 2009. London: Health Protection Agency Centre for Infections, 2009."},{"key":"R27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/221863a0","article-title":"Effect of BCG and allogeneic tumor cells on adenovirus type 12 tumorigenesis in mice","volume":"221","author":"Sj\u00f6gren","year":"1969","journal-title":"Nature"},{"key":"R28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.170.3963.1217","article-title":"Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG)","volume":"170","author":"Zbar","year":"1970","journal-title":"Science"},{"key":"R29","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.174.4015.1240","article-title":"Suppression of urethan-induced lung adenomas in mice treated with trehalose-6,6-dimycolate (cord factor) and living bacillus Calmette Gu\u00e9rin","volume":"174","author":"Bekierkunst","year":"1971","journal-title":"Science"},{"key":"R30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.172.3980.271","article-title":"Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis","volume":"172","author":"Zbar","year":"1971","journal-title":"Science"},{"key":"R31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/bmj.4.5781.189","article-title":"Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemia Committee and the Working Party on Leukaemia in Childhood","volume":"4","year":"1971","journal-title":"Br Med J"},{"key":"R32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000226046","article-title":"Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia","volume":"42","author":"Advani","year":"1985","journal-title":"Oncology"},{"key":"R33","first-page":"383","article-title":"Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase","volume":"44","author":"Baker","year":"1984","journal-title":"Cancer Res"},{"key":"R34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/1097-0142(19830915)52:6<958::AID-CNCR2820520604>3.0.CO;2-Z","article-title":"Management of adult acute leukemia. A Southwest Oncology Group study","volume":"52","author":"McCredie","year":"1983","journal-title":"Cancer"},{"key":"R35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mpo.2950110204","article-title":"Intermittent combination chemotherapy with or without bacillus Calmette-Gu\u00e9rin for treatment of acute lymphoblastic leukemia of childhood","volume":"11","author":"Odom","year":"1983","journal-title":"Med Pediatr Oncol"},{"key":"R36","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/1097-0142(19820415)49:8<1530::AID-CNCR2820490804>3.0.CO;2-1","article-title":"Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy","volume":"49","author":"Omura","year":"1982","journal-title":"Cancer"},{"key":"R37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.1973.162","article-title":"Immunotherapy for acute myelogenous leukaemia","volume":"28","author":"Powles","year":"1973","journal-title":"Br J Cancer"},{"key":"R38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(77)90549-9","article-title":"Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells","volume":"2","author":"Powles","year":"1977","journal-title":"Lancet"},{"key":"R39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.V62.3.606.606","article-title":"Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults","volume":"62","author":"Stryckmans","year":"1983","journal-title":"Blood"},{"key":"R40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/1097-0142(19830315)51:6<1083::AID-CNCR2820510619>3.0.CO;2-M","article-title":"Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study","volume":"51","author":"Jones","year":"1983","journal-title":"Cancer"},{"key":"R41","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/1097-0142(19820601)49:11<2226::AID-CNCR2820491104>3.0.CO;2-R","article-title":"Effect of methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin\u2019s disease","volume":"49","author":"Cooper","year":"1982","journal-title":"Cancer"},{"key":"R42","first-page":"1651","article-title":"Effects of combined immunotherapy with levamisole and Bacillus Calmette-Gu\u00e9rin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy","volume":"62","author":"Olkowski","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"R43","first-page":"3150","article-title":"Controlled trial of methotrexate and Bacillus Calmette-Gu\u00e9rin therapy for advanced head and neck cancer","volume":"38","author":"Papac","year":"1978","journal-title":"Cancer Res"},{"key":"R44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G","article-title":"Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial","volume":"53","author":"Buzdar","year":"1984","journal-title":"Cancer"},{"key":"R45","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/1097-0142(19820501)49:9<1754::AID-CNCR2820490904>3.0.CO;2-O","article-title":"Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast","volume":"49","author":"Cohen","year":"1982","journal-title":"Cancer"},{"key":"R46","first-page":"1685","article-title":"Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Hortobagyi","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"R47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0022-4731(85)90034-2","article-title":"Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result","volume":"23","author":"Hubay","year":"1985","journal-title":"J Steroid Biochem"},{"key":"R48","first-page":"300","article-title":"Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up","volume":"109","author":"Marshall","year":"1987","journal-title":"J Lab Clin Med"},{"key":"R49","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/BF01855129","article-title":"Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results","volume":"3","author":"Pearson","year":"1983","journal-title":"Breast Cancer Res Treat"},{"key":"R50","first-page":"84","article-title":"A pilot study on the effect of BCG vaccination in patients with bronchial carcinoma","volume":"56","author":"Nilsson","year":"1975","journal-title":"Scand J Respir Dis"},{"key":"R51","first-page":"505","article-title":"Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Gu\u00e9rin or Corynebacterium parvum in stage III lung cancer","volume":"62","author":"Bjornsson","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"R52","first-page":"5963","article-title":"Intratumoral Bacillus Calmette-Gu\u00e9rin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial","volume":"46","author":"Matthay","year":"1986","journal-title":"Cancer Res"},{"key":"R53","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/1097-0142(19861201)58:11<2411::AID-CNCR2820581110>3.0.CO;2-C","article-title":"Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer","volume":"58","author":"The Ludwig Lung Cancer Study Group (LLCSG)","year":"1986","journal-title":"Cancer"},{"key":"R54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/030089168407000107","article-title":"Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Gu\u00e9rin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma","volume":"70","author":"W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma","year":"1984","journal-title":"Tumori"},{"key":"R55","first-page":"1676","article-title":"Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen)","volume":"63","author":"The Prudente Foundation Melanoma Study Group","year":"1989","journal-title":"Cancer"},{"key":"R56","first-page":"459","article-title":"Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities","volume":"92","author":"Ariyan","year":"1982","journal-title":"Surgery"},{"key":"R57","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"key":"R58","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(74)90867-8","article-title":"Results of administering B.C.G. to patients with melanoma","volume":"2","author":"Grant","year":"1974","journal-title":"Lancet"},{"key":"R59","first-page":"177","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma","volume":"60","author":"Gutterman","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"R60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V","article-title":"Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma","volume":"51","author":"Lipton","year":"1983","journal-title":"Cancer"},{"key":"R61","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/1097-0142(197602)37:2<684::AID-CNCR2820370212>3.0.CO;2-Y","article-title":"Intralesional BCG in the treatment of metastatic malignant melanoma","volume":"37","author":"Mastrangelo","year":"1976","journal-title":"Cancer"},{"key":"R62","first-page":"33","article-title":"Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival","volume":"117","author":"McCulloch","year":"1977","journal-title":"Can Med Assoc J"},{"key":"R63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1749-6632.1976.tb41697.x","article-title":"Randomized trial of Bacillus Calmette-Gu\u00e9rin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma","volume":"277","author":"Pinsky","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"R64","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/1097-0142(19820915)50:6<1100::AID-CNCR2820500613>3.0.CO;2-6","article-title":"Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma","volume":"50","author":"Plesnicar","year":"1982","journal-title":"Cancer"},{"key":"R65","first-page":"1085","article-title":"Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study","volume":"62","author":"Ramseur","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"R66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(76)90322-1","article-title":"Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Gu\u00e9rin","volume":"21","author":"Spitler","year":"1976","journal-title":"Cell Immunol"},{"key":"R67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1097-0142(19850215)55:4<707::AID-CNCR2820550406>3.0.CO;2-5","article-title":"A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report","volume":"55","author":"Sterchi","year":"1985","journal-title":"Cancer"},{"key":"R68","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/1097-0142(19810915)48:6<1353::AID-CNCR2820480617>3.0.CO;2-N","article-title":"Treatment of disseminated malignant melanoma with high-dose oral BCG","volume":"48","author":"Varella","year":"1981","journal-title":"Cancer"},{"key":"R69","first-page":"677","article-title":"Randomized trial of adjuvant therapy for \u201chigh risk\u201d primary malignant melanoma","volume":"83","author":"Wood","year":"1978","journal-title":"Surgery"},{"key":"R70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jso.2930260204","article-title":"A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach","volume":"26","author":"Akiyoshi","year":"1984","journal-title":"J Surg Oncol"},{"key":"R71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00205355","article-title":"Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial","volume":"14","author":"Ochiai","year":"1983","journal-title":"Cancer Immunol Immunother"},{"key":"R72","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM198403223101201","article-title":"Adjuvant therapy of colon cancer--results of a prospectively randomized trial","volume":"310","author":"Gastrointestinal Tumor Study Group","year":"1984","journal-title":"N Engl J Med"},{"key":"R73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1097-0142(19840715)54:2<193::AID-CNCR2820540202>3.0.CO;2-F","article-title":"Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report","volume":"54","author":"Higgins","year":"1984","journal-title":"Cancer"},{"key":"R74","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#","article-title":"Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer","volume":"55","author":"Hoover","year":"1985","journal-title":"Cancer"},{"key":"R75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF00199367","article-title":"Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine","volume":"21","author":"Jessup","year":"1986","journal-title":"Cancer Immunol Immunother"},{"key":"R76","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/1097-0142(197512)36:6<2421::AID-CNCR2820360623>3.0.CO;2-2","article-title":"Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes\u2019 C classification. Preliminary clinical results","volume":"36","author":"Mavligit","year":"1975","journal-title":"Cancer"},{"key":"R77","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/1097-0142(197711)40:5+<2731::AID-CNCR2820400948>3.0.CO;2-W","article-title":"Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole","volume":"40","author":"Valdivieso","year":"1977","journal-title":"Cancer"},{"key":"R78","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.1976.03270200025023","article-title":"Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy","volume":"236","author":"Townsend","year":"1976","journal-title":"JAMA"},{"key":"R79","first-page":"739","article-title":"Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation","volume":"63","author":"Rosenburg","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"R80","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0090-4295(82)90464-2","article-title":"Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer","volume":"20","author":"Guinan","year":"1982","journal-title":"Urology"},{"key":"R81","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00000421-198202000-00012","article-title":"Adjuvant immunotherapy (BCG) in stage D prostate cancer","volume":"5","author":"Guinan","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R82","first-page":"157","article-title":"Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin","volume":"59","author":"Merrin","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"R83","first-page":"610","article-title":"Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects","volume":"6","author":"Adler","year":"1987","journal-title":"J Biol Response Mod"},{"key":"R84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mpo.2950030304","article-title":"The phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma","volume":"3","author":"Laucius","year":"1977","journal-title":"Med Pediatr Oncol"},{"key":"R85","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(17)59210-1","article-title":"Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney","volume":"115","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"R86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0022-5347(17)53713-1","article-title":"Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial","volume":"127","author":"Morales","year":"1982","journal-title":"J Urol"},{"key":"R87","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/1097-0142(19800901)46:5<1128::AID-CNCR2820460509>3.0.CO;2-3","article-title":"Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant","volume":"46","author":"Neidhart","year":"1980","journal-title":"Cancer"},{"key":"R88","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02565408","article-title":"Experimental percutaneous renal embolization using BCG-saturated gelfoam","volume":"5","author":"Wright","year":"1982","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R89","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"R90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","article-title":"Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"128","author":"Brosman","year":"1982","journal-title":"J Urol"},{"key":"R91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0022-5347(17)46969-2","article-title":"The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ","volume":"134","author":"Brosman","year":"1985","journal-title":"J Urol"},{"key":"R92","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0090-4295(85)90525-4","article-title":"Experience with intravesical bacillus Calmette-Gu\u00e8rin therapy of superficial bladder tumors","volume":"25","author":"Herr","year":"1985","journal-title":"Urology"},{"key":"R93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","article-title":"Bacillus Calmette-Guerin immunotherapy for bladder cancer","volume":"134","author":"Lamm","year":"1985","journal-title":"J Urol"},{"key":"R94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"R95","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0022-5347(17)53283-8","article-title":"Bladder cancer immunotherapy","volume":"128","author":"Lamm","year":"1982","journal-title":"J Urol"},{"key":"R96","first-page":"47","article-title":"Intravesical administration of bacillus Calmette-Gu\u00e9rin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"R97","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.20166","article-title":"Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group","volume":"100","author":"Agarwala","year":"2004","journal-title":"Cancer"},{"key":"R98","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.1993.11.3.390","article-title":"Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial","volume":"11","author":"Hoover","year":"1993","journal-title":"J Clin Oncol"},{"key":"R99","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.2000.18.1.148","article-title":"Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283","volume":"18","author":"Harris","year":"2000","journal-title":"J Clin Oncol"},{"key":"R100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0090-4295(91)80362-B","article-title":"Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin or adriamycin. Results of long-term follow-up","volume":"38","author":"Khanna","year":"1991","journal-title":"Urology"},{"key":"R101","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000281212","article-title":"A trial of bacillus Calmette-Gu\u00e9rin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study","volume":"41","author":"Mori","year":"1986","journal-title":"Urol Int"},{"key":"R102","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"R103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000281695","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study","volume":"45","author":"Melekos","year":"1990","journal-title":"Urol Int"},{"key":"R104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano","year":"1995","journal-title":"Eur Urol"},{"key":"R105","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0022-5347(01)65458-2","article-title":"Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy","volume":"156","author":"Hurle","year":"1996","journal-title":"J Urol"},{"key":"R106","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"R107","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"R108","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(17)38379-9","article-title":"Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma","volume":"145","author":"D\u2019Ancona","year":"1991","journal-title":"J Urol"},{"key":"R109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(17)39367-9","article-title":"A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer","volume":"144","author":"Lamm","year":"1990","journal-title":"J Urol"},{"key":"R110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"L\u00fcftenegger","year":"1996","journal-title":"J Urol"},{"key":"R111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000282516","article-title":"Use of maintenance intravesical bacillus Calmette-Gu\u00e9rin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study","volume":"51","author":"Witjes","year":"1993","journal-title":"Urol Int"},{"key":"R112","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","article-title":"Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule","volume":"149","author":"Melekos","year":"1993","journal-title":"J Urol"},{"key":"R113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.urolonc.2010.02.007","article-title":"Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations","volume":"30","author":"Librenjak","year":"2012","journal-title":"Urol Oncol"},{"key":"R114","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.1990.8.4.608","article-title":"Adjuvant bacillus Calmette-Gu\u00e9rin therapy in non-Hodgkin\u2019s malignant lymphomas: long-term results of a randomized trial in a single institution","volume":"8","author":"Ravaud","year":"1990","journal-title":"J Clin Oncol"},{"key":"R115","first-page":"41","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy in ovarian cancer","volume":"33","author":"Pattillo","year":"1988","journal-title":"J Reprod Med"},{"key":"R116","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0090-8258(90)90244-F","article-title":"A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study","volume":"39","author":"Creasman","year":"1990","journal-title":"Gynecol Oncol"},{"key":"R117","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1349-7006.2009.01271.x","article-title":"Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin: effect of lymphadenectomy","volume":"100","author":"Hayashi","year":"2009","journal-title":"Cancer Sci"},{"key":"R118","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"R119","doi-asserted-by":"crossref","DOI":"10.4161\/onci.20459","article-title":"Trial Watch - Immunostimulatory cytokines","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunol"},{"key":"R120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4161\/onci.1.2.19026","article-title":"Trial Watch - Chemotherapy with immunogenic cell death inducers","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunol"},{"key":"R121","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4161\/onci.19549","article-title":"Trial Watch - Adoptive cell transfer immunotherapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunol"},{"key":"R122","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/onci.1.1.17938","article-title":"Trial Watch - Monoclonal antibodies in cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunol"},{"key":"R123","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/179314a0","article-title":"Stimulation of non-specific immunity by the lipid A component of bacterial lipopolysaccharide","volume":"179","author":"Howard","year":"1957","journal-title":"Nature"},{"key":"R124","first-page":"181","article-title":"Investigations on the mechanism of stimulation of non-specific immunity by bacterial lipopolysaccharides","volume":"1","author":"Howard","year":"1958","journal-title":"Immunology"},{"key":"R125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/bi00891a018","article-title":"Purification and characterization of the lipid A component of the lipopolysaccharides from Escherichia Coli","volume":"3","author":"Burton","year":"1964","journal-title":"Biochemistry"},{"key":"R126","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/JB.94.6.1824-1836.1967","article-title":"Endotoxic glycolipid from a heptoseless mutant of Salmonella minnesota","volume":"94","author":"Kasai","year":"1967","journal-title":"J Bacteriol"},{"key":"R127","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/JB.94.5.1320-1326.1967","article-title":"Biologically active endotoxins from Salmonella mutants deficient in O- and R-polysaccharides and heptose","volume":"94","author":"Kim","year":"1967","journal-title":"J Bacteriol"},{"key":"R128","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1432-1033.1969.tb19618.x","article-title":"Biochemical studies on lipopolysaccharides of Salmonella R mutants. 6. Investigations on the structure of the lipid A component","volume":"7","author":"Gmeiner","year":"1969","journal-title":"Eur J Biochem"},{"key":"R129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0005-2760(70)90128-1","article-title":"Structural features of lipid A preparations isolated from Escherichia coli and Shigella flexneri","volume":"202","author":"Adams","year":"1970","journal-title":"Biochim Biophys Acta"},{"key":"R130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1139\/o70-010","article-title":"The chemical constitution of lipid A from Serratia marcescens","volume":"48","author":"Adams","year":"1970","journal-title":"Can J Biochem"},{"key":"R131","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1128\/JB.112.1.268-275.1972","article-title":"Site of action of lipid A on mitochondria","volume":"112","author":"Kato","year":"1972","journal-title":"J Bacteriol"},{"key":"R132","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/IAI.8.3.406-411.1973","article-title":"In vitro transformation of mouse bone-marrow-derived (B) lymphocytes induced by the lipid component of endotoxin","volume":"8","author":"Rosenstreich","year":"1973","journal-title":"Infect Immun"},{"key":"R133","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jcp.1040870110","article-title":"Lipid A, the active part of bacterial endotoxins in inducing serum colony stimulating activity and proliferation of splenic granulocyte\/macrophage progenitor cells","volume":"87","author":"Apte","year":"1976","journal-title":"J Cell Physiol"},{"key":"R134","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1084\/jem.146.2.611","article-title":"Immunostimulators induce granulocyte\/macrophage colony-stimulating activity and block proliferation in a monocyte tumor cell line","volume":"146","author":"Ralph","year":"1977","journal-title":"J Exp Med"},{"key":"R135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1348-0421.1961.tb00214.x","article-title":"Studies on the anti-tumor effect of the bacterial lipid component, lipid A. I. On some physicochemical properties and antitumor activity of lipid A fraction","volume":"5","author":"Kasai","year":"1961","journal-title":"Jpn J Microbiol"},{"key":"R136","first-page":"287","article-title":"[Study on the antineoplastic action of the bacterial lipid, \u201clipid A\u201d]","volume":"49","author":"Kawanishi","year":"1962","journal-title":"Nisshin Igaku Jpn J Med Prog"},{"key":"R137","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1432-1033.1979.tb13152.x","article-title":"Regions of the lipopolysaccharide of Pseudomonas aeruginosa essential for antitumor and interferon-inducing activities","volume":"97","author":"Tanamoto","year":"1979","journal-title":"Eur J Biochem"},{"key":"R138","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1620\/tjem.144.385","article-title":"Role of lipid A in the production of tumor necrosis factor and differences in antitumor activity between tumor necrosis factor and lipopolysaccharide","volume":"144","author":"Haranaka","year":"1984","journal-title":"Tohoku J Exp Med"},{"key":"R139","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0161-5890(85)90164-6","article-title":"Role of lipid A of endotoxin in the production of tumour necrosis factor","volume":"22","author":"Ha","year":"1985","journal-title":"Mol Immunol"},{"key":"R140","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/bjc.1973.45","article-title":"Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA","volume":"27","author":"Parr","year":"1973","journal-title":"Br J Cancer"},{"key":"R141","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"R142","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/26239","article-title":"Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling","volume":"395","author":"Yang","year":"1998","journal-title":"Nature"},{"key":"R143","first-page":"2654","article-title":"Isolation of a nontoxic lipid A fraction containing tumor regression activity","volume":"41","author":"Takayama","year":"1981","journal-title":"Cancer Res"},{"key":"R144","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1432-1033.1984.tb08364.x","article-title":"Biological activities of analogues of lipid A based chemically on the revised structural model. Comparison of mediator-inducing, immunomodulating and endotoxic activities","volume":"143","author":"Kanegasaki","year":"1984","journal-title":"Eur J Biochem"},{"key":"R145","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0014-5793(84)80131-3","article-title":"Biological activities of chemically synthesized analogues of the nonreducing sugar moiety of lipid A","volume":"167","author":"Matsuura","year":"1984","journal-title":"FEBS Lett"},{"key":"R146","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/IAI.49.1.225-237.1985","article-title":"Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli re-mutant","volume":"49","author":"Kotani","year":"1985","journal-title":"Infect Immun"},{"key":"R147","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/oxfordjournals.jbchem.a135389","article-title":"Biological activities of chemically synthesized partial structure analogues of lipid A","volume":"98","author":"Matsuura","year":"1985","journal-title":"J Biochem"},{"key":"R148","first-page":"43","article-title":"Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27","volume":"26","author":"Nakatsuka","year":"1988","journal-title":"J Clin Lab Immunol"},{"key":"R149","doi-asserted-by":"crossref","first-page":"11808","DOI":"10.1016\/S0021-9258(18)33836-5","article-title":"Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium","volume":"257","author":"Qureshi","year":"1982","journal-title":"J Biol Chem"},{"key":"R150","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1016\/S0021-9258(18)89017-2","article-title":"Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination","volume":"260","author":"Qureshi","year":"1985","journal-title":"J Biol Chem"},{"key":"R151","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/clinids\/6.4.567","article-title":"Lipid A and immunotherapy","volume":"6","author":"Ribi","year":"1984","journal-title":"Rev Infect Dis"},{"key":"R152","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00205743","article-title":"Phase-I study of intravenous modified lipid A","volume":"18","author":"Vosika","year":"1984","journal-title":"Cancer Immunol Immunother"},{"key":"R153","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0192-0561(86)90088-3","article-title":"Relationship between immune system and gram-negative bacteria. Acid-treated Salmonella minnesota R595 (Re) enhances immune responsiveness in patients with gynecologic malignancies","volume":"8","author":"Jirillo","year":"1986","journal-title":"Int J Immunopharmacol"},{"key":"R154","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/030089168707300509","article-title":"Pilot study of intravenous administration of the acid-treated Salmonella minnesota R595 (Re) in cancer patients","volume":"73","author":"Jirillo","year":"1987","journal-title":"Tumori"},{"key":"R155","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0016-5085(91)90532-P","article-title":"Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat","volume":"101","author":"Jeannin","year":"1991","journal-title":"Gastroenterology"},{"key":"R156","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/83.17.1240","article-title":"Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine","volume":"83","author":"Johnston","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"R157","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0192-0561(91)90083-J","article-title":"Combined effects of synthetic lipid A analogs and muramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice","volume":"13","author":"Shimizu","year":"1991","journal-title":"Int J Immunopharmacol"},{"key":"R158","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0192-0561(94)90043-4","article-title":"Antitumor effect of DT-5461a, a synthetic low-toxicity lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation","volume":"16","author":"Akimoto","year":"1994","journal-title":"Int J Immunopharmacol"},{"key":"R159","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01525505","article-title":"Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects","volume":"38","author":"Yang","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"R160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00006676-199604000-00008","article-title":"Effects of a new synthetic lipid A on endogenous tumor necrosis factor production and antitumor activity against human pancreatic cancer cells","volume":"12","author":"Satake","year":"1996","journal-title":"Pancreas"},{"key":"R161","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3109\/07357909709047593","article-title":"Antitumor effect of DT-5461, a lipid A derivative, against human tumor xenografts is mediated by intratumoral production of tumor necrosis factor and affected by host immunosuppressive factors in nude mice","volume":"15","author":"Kumazawa","year":"1997","journal-title":"Cancer Invest"},{"key":"R162","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00001813-199706000-00013","article-title":"A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells","volume":"8","author":"Kuramitsu","year":"1997","journal-title":"Anticancer Drugs"},{"key":"R163","first-page":"4283","article-title":"Intratumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog","volume":"18","author":"Matsumoto","year":"1998","journal-title":"Anticancer Res"},{"key":"R164","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00002371-199909000-00003","article-title":"Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats","volume":"22","author":"Mizushima","year":"1999","journal-title":"J Immunother"},{"key":"R165","first-page":"181","article-title":"Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL","volume":"10","author":"Silla","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"R166","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00008390-200108000-00002","article-title":"Optimization of intracerebral tumour protection by active-specific immunization against murine melanoma B16\/G3.12","volume":"11","author":"Staib","year":"2001","journal-title":"Melanoma Res"},{"key":"R167","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00464-001-8187-6","article-title":"Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer","volume":"16","author":"Kirman","year":"2002","journal-title":"Surg Endosc"},{"key":"R168","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00262-001-0241-7","article-title":"Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity","volume":"50","author":"Satoh","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"R169","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14760584.2.2.219","article-title":"Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529","volume":"2","author":"Evans","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"R170","first-page":"355","article-title":"Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer","volume":"13","author":"Larmonier","year":"2004","journal-title":"Int J Mol Med"},{"key":"R171","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.intimp.2005.02.013","article-title":"Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions","volume":"5","author":"D\u2019Agostini","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"R172","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.178.5.2721","article-title":"Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells","volume":"178","author":"Hermans","year":"2007","journal-title":"J Immunol"},{"key":"R173","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1158\/0008-5472.CAN-07-0079","article-title":"Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo","volume":"67","author":"Andreani","year":"2007","journal-title":"Cancer Res"},{"key":"R174","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00262-010-0843-z","article-title":"Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential","volume":"59","author":"ten Brinke","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"R175","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/13543784.7.9.1475","article-title":"QS-21: a water-soluble triterpene glycoside adjuvant","volume":"7","author":"Kensil","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"R176","first-page":"397","article-title":"Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide","volume":"6","author":"de Bono","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R177","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting Toll-like receptors: emerging therapeutics?","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"R178","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.4049\/jimmunol.172.5.3289","article-title":"Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients","volume":"172","author":"Atanackovic","year":"2004","journal-title":"J Immunol"},{"key":"R179","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"R180","first-page":"4","article-title":"Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA","volume":"4","author":"Li\u00e9nard","year":"2004","journal-title":"Cancer Immun"},{"key":"R181","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00002371-200403000-00006","article-title":"Immunologic analysis of a phase I\/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors","volume":"27","author":"Vantomme","year":"2004","journal-title":"J Immunother"},{"key":"R182","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1073\/pnas.0707140104","article-title":"Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming","volume":"105","author":"Atanackovic","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R183","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4419-1603-7_10","article-title":"Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results","volume":"667","author":"Cluff","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"R184","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"R185","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"R186","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"R187","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"R188","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R189","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"key":"R190","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12325-009-0079-5","article-title":"Clinical update of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine, Cervarix","volume":"26","author":"Schwarz","year":"2009","journal-title":"Adv Ther"},{"key":"R191","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"key":"R192","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years","volume":"25","author":"Kim","year":"2010","journal-title":"J Korean Med Sci"},{"key":"R193","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"key":"R194","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"R195","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.1016\/j.vaccine.2011.08.037","article-title":"Co-administration of human papillomavirus-16\/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls","volume":"29","author":"Schmeink","year":"2011","journal-title":"Vaccine"},{"key":"R196","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"R197","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"R198","doi-asserted-by":"crossref","first-page":"abstr 9065","DOI":"10.1200\/jco.2008.26.15_suppl.9065","article-title":"Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)","volume":"26(Suppl)","author":"Kruit","year":"2008","journal-title":"J Clin Oncol"},{"key":"R199","doi-asserted-by":"crossref","first-page":"abstr 9045","DOI":"10.1200\/jco.2008.26.15_suppl.9045","article-title":"Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031)","volume":"26(Suppl)","author":"Louhaed","year":"2008","journal-title":"J Clin Oncol"},{"key":"R200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1470-2045(11)70324-2","article-title":"Success of HPV vaccination is now a matter of coverage","volume":"13","author":"Schiffman","year":"2012","journal-title":"Lancet Oncol"},{"key":"R201","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1128\/AAC.32.5.678","article-title":"Efficacy of S26308 against guinea pig cytomegalovirus infection","volume":"32","author":"Chen","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"R202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0166-3542(88)90032-0","article-title":"Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection","volume":"10","author":"Harrison","year":"1988","journal-title":"Antiviral Res"},{"key":"R203","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1128\/AAC.33.9.1511","article-title":"Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections","volume":"33","author":"Bernstein","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R204","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0166-3542(91)90012-G","article-title":"Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs","volume":"15","author":"Harrison","year":"1991","journal-title":"Antiviral Res"},{"key":"R205","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/infdis\/167.3.731","article-title":"Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs","volume":"167","author":"Bernstein","year":"1993","journal-title":"J Infect Dis"},{"key":"R206","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0166-3542(93)90058-Q","article-title":"Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development","volume":"20","author":"Bernstein","year":"1993","journal-title":"Antiviral Res"},{"key":"R207","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jlb.55.2.234","article-title":"Cytokine induction in mice by the immunomodulator imiquimod","volume":"55","author":"Reiter","year":"1994","journal-title":"J Leukoc Biol"},{"key":"R208","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/jir.1995.15.537","article-title":"Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609","volume":"15","author":"Gibson","year":"1995","journal-title":"J Interferon Cytokine Res"},{"key":"R209","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1128\/MCB.15.4.2207","article-title":"Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways","volume":"15","author":"Megyeri","year":"1995","journal-title":"Mol Cell Biol"},{"key":"R210","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jlb.58.3.365","article-title":"Cytokine induction by the immunomodulators imiquimod and S-27609","volume":"58","author":"Testerman","year":"1995","journal-title":"J Leukoc Biol"},{"key":"R211","first-page":"3528","article-title":"Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine","volume":"52","author":"Sidky","year":"1992","journal-title":"Cancer Res"},{"key":"R212","first-page":"5176","article-title":"Phase I trial of an oral immunomodulator and interferon inducer in cancer patients","volume":"53","author":"Witt","year":"1993","journal-title":"Cancer Res"},{"key":"R213","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjc.1996.569","article-title":"A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily","volume":"74","author":"Savage","year":"1996","journal-title":"Br J Cancer"},{"key":"R214","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1067\/mjd.2002.123492","article-title":"Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis","volume":"47","author":"Persaud","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1067\/mjd.2002.126257","article-title":"Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial","volume":"47","author":"Salasche","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R216","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00403-004-0465-4","article-title":"Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms","volume":"296","author":"Harrison","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"R217","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R218","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-a","article-title":"Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study","volume":"140","author":"Stockfleth","year":"2004","journal-title":"Arch Dermatol"},{"key":"R219","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"key":"R221","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R222","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","article-title":"Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial","volume":"44","author":"Marks","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R223","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study","volume":"47","author":"Geisse","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R224","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archderm.138.9.1165","article-title":"Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens","volume":"138","author":"Shumack","year":"2002","journal-title":"Arch Dermatol"},{"key":"R225","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","article-title":"Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion","volume":"147","author":"Sterry","year":"2002","journal-title":"Br J Dermatol"},{"key":"R226","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R227","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1524-4725.2004.30116.x","article-title":"Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series","volume":"30","author":"Huber","year":"2004","journal-title":"Dermatol Surg"},{"key":"R228","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/archderm.140.10.1284-b","article-title":"Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas","volume":"140","author":"Marks","year":"2004","journal-title":"Arch Dermatol"},{"key":"R229","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2230.2004.01456.x","article-title":"Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients","volume":"29","author":"Vidal","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"R230","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2230.2004.01601.x","article-title":"Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma","volume":"29","author":"Vidal","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"R231","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9343(97)00181-2","article-title":"Therapeutic approaches to genital warts","volume":"102","author":"Beutner","year":"1997","journal-title":"Am J Med"},{"key":"R232","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0190-9622(98)70243-9","article-title":"Treatment of genital warts with an immune-response modifier (imiquimod)","volume":"38","author":"Beutner","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"R233","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R234","first-page":"S14","article-title":"Imiquimod in clinical practice","volume":"39","author":"Edwards","year":"1998","journal-title":"Australas J Dermatol"},{"key":"R235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.134.1.25","article-title":"Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus","volume":"134","author":"Edwards","year":"1998","journal-title":"Arch Dermatol"},{"key":"R236","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1346-8138.1998.tb02429.x","article-title":"Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Syed","year":"1998","journal-title":"J Dermatol"},{"key":"R237","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/517472","article-title":"A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod","volume":"178","author":"Tyring","year":"1998","journal-title":"J Infect Dis"},{"key":"R238","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/00002030-199912030-00011","article-title":"A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients","volume":"13","author":"Gilson","year":"1999","journal-title":"AIDS"},{"key":"R239","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1365-2133.2000.03777.x","article-title":"Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum","volume":"143","author":"Hengge","year":"2000","journal-title":"Br J Dermatol"},{"key":"R240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/jinf.2000.0709","article-title":"Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study","volume":"41","author":"Syed","year":"2000","journal-title":"J Infect"},{"key":"R241","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nri3027","article-title":"Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?","volume":"11","author":"Reizis","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"R242","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.jid.5700286","article-title":"The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion","volume":"126","author":"Sch\u00f6n","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R243","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1172\/JCI61034","article-title":"Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells","volume":"122","author":"Drobits","year":"2012","journal-title":"J Clin Invest"},{"key":"R244","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2004.04.022","article-title":"Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream","volume":"51","author":"Welsh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaad.2006.06.011","article-title":"Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study","volume":"56","author":"Ho","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R246","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2230.2007.02676.x","article-title":"Involution of infantile haemangiomas after imiquimod 5% cream","volume":"33","author":"Barry","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"R247","first-page":"E21","article-title":"Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases","volume":"89","author":"Senchak","year":"2010","journal-title":"Ear Nose Throat J"},{"key":"R248","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1525-1470.2011.01520.x","article-title":"A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma","volume":"28","author":"Jiang","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"R249","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1365-2133.2000.03787.x","article-title":"Imiquimod: a novel treatment for lentigo maligna","volume":"143","author":"Ahmed","year":"2000","journal-title":"Br J Dermatol"},{"key":"R250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.0366-077X.2003.05637.x","article-title":"Treatment of lentigo maligna with topical imiquimod","volume":"149","author":"Naylor","year":"2003","journal-title":"Br J Dermatol"},{"key":"R251","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2133.2004.05983.x","article-title":"A pilot study of treatment of lentigo maligna with 5% imiquimod cream","volume":"151","author":"Fleming","year":"2004","journal-title":"Br J Dermatol"},{"key":"R252","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/archderm.141.4.510","article-title":"Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod","volume":"141","author":"Wolf","year":"2005","journal-title":"Arch Dermatol"},{"key":"R253","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-4632.2005.02582.x","article-title":"Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream","volume":"44","author":"Ray","year":"2005","journal-title":"Int J Dermatol"},{"key":"R254","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-4632.2008.03562.x","article-title":"Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna","volume":"47","author":"Bassukas","year":"2008","journal-title":"Int J Dermatol"},{"key":"R255","first-page":"56","article-title":"Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study","volume":"5","author":"Dusza","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"R256","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1524-4725.2007.34031.x","article-title":"Treatment of lentigo maligna with imiquimod before staged excision","volume":"34","author":"Cotter","year":"2008","journal-title":"Dermatol Surg"},{"key":"R257","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archdermatol.2011.260","article-title":"Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients","volume":"147","author":"Ly","year":"2011","journal-title":"Arch Dermatol"},{"key":"R258","doi-asserted-by":"crossref","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"key":"R259","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1067\/mjd.2001.111335","article-title":"Imiquimod 5% cream in the treatment of Bowen\u2019s disease","volume":"44","author":"Mackenzie-Wood","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1524-4725.2001.00199.x","article-title":"Bowen\u2019s disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy","volume":"27","author":"Smith","year":"2001","journal-title":"Dermatol Surg"},{"key":"R261","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2230.28.s1.4.x","article-title":"Treatment of Bowen\u2019s disease using a cycle regimen of imiquimod 5% cream","volume":"28","author":"Chen","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"R262","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2006.06.031","article-title":"Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy","volume":"55","author":"Ondo","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R263","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaad.2006.04.004","article-title":"Imiquimod 5% cream in the treatment of Bowen\u2019s disease and invasive squamous cell carcinoma","volume":"55","author":"Peris","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R264","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/AOG.0b013e318236f1a0","article-title":"Treatment of multifocal Bowen\u2019s disease in immunocompromised women with surgery and topical imiquimod","volume":"119","author":"Kaushal","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R265","first-page":"80","article-title":"Topical treatment with imiquimod may induce regression of facial keratoacanthoma","volume":"13","author":"Dendorfer","year":"2003","journal-title":"Eur J Dermatol"},{"key":"R266","first-page":"71","article-title":"Imiquimod as a possible treatment for keratoacanthoma","volume":"3","author":"Bhatia","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"R267","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1468-3083.2004.01025.x","article-title":"Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream","volume":"18","author":"Di Lernia","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R268","first-page":"347","article-title":"Treatment of non-genital warts with topical imiquimod 5% cream","volume":"12","author":"Muzio","year":"2002","journal-title":"Eur J Dermatol"},{"key":"R269","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2230.2003.01213.x","article-title":"Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus","volume":"28","author":"Hagman","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"R270","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1258\/002221503322334576","article-title":"Medical treatment of nasal squamous papilloma with imiquimod cream","volume":"117","author":"Caversaccio","year":"2003","journal-title":"J Laryngol Otol"},{"key":"R271","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/09546630310016763","article-title":"An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts","volume":"14","author":"Micali","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"R272","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0022215108002570","article-title":"Successful treatment of intranasal papillomata with imiquimod cream in a human immunodeficiency virus positive patient","volume":"123","author":"Fern\u00e1ndez-Casado","year":"2009","journal-title":"J Laryngol Otol"},{"key":"R273","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1524-4725.2002.01196.x","article-title":"Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream","volume":"28","author":"Weisberg","year":"2002","journal-title":"Dermatol Surg"},{"key":"R274","first-page":"3031","article-title":"Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%","volume":"7","author":"Diaz-Arrastia","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R275","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/gyno.2001.6539","article-title":"The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia","volume":"85","author":"Todd","year":"2002","journal-title":"Gynecol Oncol"},{"key":"R276","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2003.09.013","article-title":"Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia","volume":"92","author":"Todd","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R277","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archderm.140.10.1220","article-title":"Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases","volume":"140","author":"Wendling","year":"2004","journal-title":"Arch Dermatol"},{"key":"R278","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ajog.2005.08.022","article-title":"Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2\/3","volume":"194","author":"Le","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R279","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2007.06.003","article-title":"Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study","volume":"107","author":"Mathiesen","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R280","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa072685","article-title":"Treatment of vulvar intraepithelial neoplasia with topical imiquimod","volume":"358","author":"van Seters","year":"2008","journal-title":"N Engl J Med"},{"key":"R281","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br J Cancer"},{"key":"R282","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0b013e32833d466c","article-title":"A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod","volume":"24","author":"Fox","year":"2010","journal-title":"AIDS"},{"key":"R283","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2010.12.340","article-title":"Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial","volume":"121","author":"Terlou","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R284","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajog.2011.06.105","article-title":"Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia","volume":"206","author":"Pachman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R285","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/01.smj.0000209223.68763.b1","article-title":"Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review","volume":"99","author":"Cohen","year":"2006","journal-title":"South Med J"},{"key":"R286","first-page":"811","article-title":"Imiquimod in vulvar Paget\u2019s disease: a case report","volume":"53","author":"Geisler","year":"2008","journal-title":"J Reprod Med"},{"key":"R287","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0b013e31815a58a5","article-title":"Complete resolution of Paget disease of the vulva with imiquimod cream","volume":"12","author":"Hatch","year":"2008","journal-title":"J Low Genit Tract Dis"},{"key":"R288","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1468-3083.2009.03451.x","article-title":"Successful treatment of three cases of primary extramammary Paget\u2019s disease of the vulva with Imiquimod--proposal of a therapeutic schedule","volume":"24","author":"Sendagorta","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R289","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/LGT.0b013e31822d2484","article-title":"Conservative management of extramammary paget disease with imiquimod","volume":"16","author":"Baiocchi","year":"2012","journal-title":"J Low Genit Tract Dis"},{"key":"R290","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-3062.2007.00239.x","article-title":"Development of Kaposi\u2019s sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod","volume":"10","author":"Babel","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"R291","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaad.2007.11.005","article-title":"Imiquimod 5% cream for treatment of HIV-negative Kaposi\u2019s sarcoma skin lesions: A phase I to II, open-label trial in 17 patients","volume":"58","author":"C\u00e9lestin Schartz","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R292","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2230.2011.04278.x","article-title":"Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation","author":"Prinz Vavricka","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"R293","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5021\/ad.2011.23.2.229","article-title":"Imiquimod as an adjuvant treatment measure for desmoplastic trichoepithelioma","volume":"23","author":"Seo","year":"2011","journal-title":"Ann Dermatol"},{"key":"R294","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1365-2133.2004.05993.x","article-title":"Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara)","volume":"150","author":"Didona","year":"2004","journal-title":"Br J Dermatol"},{"key":"R295","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors","year":"2006","journal-title":"Eur J Dermatol"},{"key":"R296","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00128071-200607030-00002","article-title":"Management of refractory early-stage cutaneous T-cell lymphoma","volume":"7","author":"Huber","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"R297","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000063904","article-title":"Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma","volume":"205","author":"Bong","year":"2002","journal-title":"Dermatology"},{"key":"R298","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br J Dermatol"},{"key":"R299","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2133.2008.08709.x","article-title":"Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1\/Th2 balance in patients with metastatic melanoma","volume":"159","author":"Green","year":"2008","journal-title":"Br J Dermatol"},{"key":"R300","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1529-8019.2011.01423.x","article-title":"Imiquimod 5% cream for the treatment of nasal lesion of metastatic renal cell carcinoma","volume":"24","author":"Asakura","year":"2011","journal-title":"Dermatol Ther"},{"key":"R301","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0b013e328345e95e","article-title":"Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream","volume":"21","author":"Garcia","year":"2011","journal-title":"Melanoma Res"},{"key":"R302","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"Adams","year":"2008","journal-title":"J Immunol"},{"key":"R303","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/pros.20941","article-title":"Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer","volume":"69","author":"Feyerabend","year":"2009","journal-title":"Prostate"},{"key":"R304","first-page":"598","article-title":"TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases","volume":"12","author":"Hibbitts","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"R305","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R306","first-page":"20","article-title":"Safety and efficacy of multiple 16-week courses of topical imiquimod for the treatment of large areas of skin involved with actinic keratoses","volume":"2","author":"Del Rosso","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"R307","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles","volume":"62","author":"Hanke","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R308","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1745-6215-11-42","article-title":"The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma","volume":"11","author":"Ozolins","year":"2010","journal-title":"Trials"},{"key":"R309","first-page":"318","article-title":"Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study","volume":"85","author":"Quirk","year":"2010","journal-title":"Cutis"},{"key":"R310","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"}],"container-title":["OncoImmunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/onci.20931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T23:45:23Z","timestamp":1642463123000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/onci.20931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":310,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,10,28]]},"published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.4161\/onci.20931"],"URL":"https:\/\/doi.org\/10.4161\/onci.20931","relation":{},"ISSN":["2162-402X"],"issn-type":[{"value":"2162-402X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}